Abstract
Recent studies have proven that the purinergic signaling pathway plays a key role in neurotransmission and neuromodulation, and is involved in various neurodegenerative diseases and psychiatric disorders. With the characterization of the subtypes of receptors in purinergic signaling, i.e. the P1 (adenosine), P2X (ion channel) and P2Y (G protein-coupled), more attention has been paid to the pathophysiology and therapeutic potential of purinergic signaling in the central nervous system disorders. Alzheimer’s disease (AD) is a progressive and deadly neurodegenerative disease that is characterized by memory loss, cognitive impairment and dementia. However, as drug development aimed to prevent or control AD has series of failures in recent years, more researchers have focused on the neuroprotection-related mechanisms such as purinergic signaling in AD patients to find a potential cure. This article reviews the recent discoveries of purinergic signaling in AD, and summarizes the potential agents as modulators for the receptors of purinergic signaling in AD-related research and treatments. Thus, our paper provides an insight into purinergic signaling in the development of anti- AD therapies.
Keywords: Purinergic signaling, central nervous system disorders, Alzheimer’s disease, purinergic receptors, therapentic modulators, neuro modulation.
Mini-Reviews in Medicinal Chemistry
Title:The Therapeutic Potential of Purinergic Receptors in Alzheimer’s Disease and Promising Therapeutic Modulators
Volume: 21 Issue: 11
Author(s): Lili Pan, Yu Ma, Yunchun Li, Haoxing Wu, Rui Huang, Zhengxin Cai and Xiaoai Wu*
Affiliation:
- Department of Nuclear Medicine, Laboratory of Clinical Nuclear Medicine, West China Hospital, Sichuan University, Chengdu 610041, Sichuan,China
Keywords: Purinergic signaling, central nervous system disorders, Alzheimer’s disease, purinergic receptors, therapentic modulators, neuro modulation.
Abstract: Recent studies have proven that the purinergic signaling pathway plays a key role in neurotransmission and neuromodulation, and is involved in various neurodegenerative diseases and psychiatric disorders. With the characterization of the subtypes of receptors in purinergic signaling, i.e. the P1 (adenosine), P2X (ion channel) and P2Y (G protein-coupled), more attention has been paid to the pathophysiology and therapeutic potential of purinergic signaling in the central nervous system disorders. Alzheimer’s disease (AD) is a progressive and deadly neurodegenerative disease that is characterized by memory loss, cognitive impairment and dementia. However, as drug development aimed to prevent or control AD has series of failures in recent years, more researchers have focused on the neuroprotection-related mechanisms such as purinergic signaling in AD patients to find a potential cure. This article reviews the recent discoveries of purinergic signaling in AD, and summarizes the potential agents as modulators for the receptors of purinergic signaling in AD-related research and treatments. Thus, our paper provides an insight into purinergic signaling in the development of anti- AD therapies.
Export Options
About this article
Cite this article as:
Pan Lili , Ma Yu , Li Yunchun , Wu Haoxing , Huang Rui , Cai Zhengxin and Wu Xiaoai *, The Therapeutic Potential of Purinergic Receptors in Alzheimer’s Disease and Promising Therapeutic Modulators, Mini-Reviews in Medicinal Chemistry 2021; 21 (11) . https://dx.doi.org/10.2174/1389557520999201209211610
DOI https://dx.doi.org/10.2174/1389557520999201209211610 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Mitochondria as a Therapeutic Target in Metabolic Disorders
Mitochondria are the primary site of adenosine triphosphate (ATP) production in mammalian cells. Moreover, these organelles are an important source of reactive oxygen and nitrogen species in virtually any nucleated cell type. The modulation of a myriad of cellular signaling pathways depends on the mitochondrial physiology. Mitochondrial dysfunction is observed ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Biological Properties and Therapeutic Potential of Bilirubin
Mini-Reviews in Medicinal Chemistry A Link Between Chemical Structure and Biological Activity in Triterpenoids
Recent Patents on Anti-Cancer Drug Discovery No-reflow: Incidence and Detection in The Cath-Lab
Current Pharmaceutical Design Current Management of Intermittent Claudication: The Role of Pharmacological and Nonpharmacological Symptom-Directed Therapies
Current Vascular Pharmacology Preventing Vascular Graft Failure: Endothelial Cell Seeding and Tissue Engineering
Vascular Disease Prevention (Discontinued) The Endocannabinoid System and Heart Disease: The Role of Cannabinoid Receptor Type 2
Cardiovascular & Hematological Disorders-Drug Targets Cardiovascular Diseases and the Nitric Oxide Pathway
Current Vascular Pharmacology Therapeutic Potential of Natural Compounds that Regulate the Activity of Protein Kinase C
Current Medicinal Chemistry Pleiotropic Actions of PPARg Activators Thiazolidinediones in Cardiovascular Diseases
Current Pharmaceutical Design Nesfatin-1 and the Cardiovascular System: Central and Pheripheral Actions and Cardioprotection
Current Drug Targets Anticancer Agents Derived from Natural Products
Mini-Reviews in Medicinal Chemistry Targeting Mitochondria in Cardiovascular Diseases
Current Pharmaceutical Design Near Infrared Spectroscopy in Healthy Preterm and Term Newborns: Correlation with Gestational Age and Standard Monitoring Parameters
Current Neurovascular Research Fragmented ECG as a Risk Marker in Cardiovascular Diseases
Current Cardiology Reviews Signaling Epicenters: The Role of Caveolae and Caveolins in Volatile Anesthetic Induced Cardiac Protection
Current Pharmaceutical Design Editorial (Hot Topic: New Insights into Insulin Resistance, Cardiovascular Diseases and Oxidative Stress: Pathophysiological and Clinical Consequences)
Current Pharmaceutical Design Transdermal Nutraceuticals Delivery System for CNS Disease
CNS & Neurological Disorders - Drug Targets Surgical Complications of Hyperglycaemia
Current Diabetes Reviews Current Treatment of the Pulmonary Arterial Hypertension
Current Respiratory Medicine Reviews Ginkgo biloba as an Alternative Medicine in the Treatment of Anxiety in Dementia and other Psychiatric Disorders
Current Drug Metabolism